identif
suitabl
biolog
drug
target
primari
step
toward
therapeut
valid
combin
structur
comput
varieti
drug
target
identifi
host
encas
lipid
envelop
filovirus
filament
linear
nonseg
rna
encod
genom
contain
genet
inform
seven
structur
protein
consid
potenti
drug
target
name
transcript
activ
polymeras
cofactor
matrix
protein
nucleoprotein
np
glycoprotein
gp
rna
polymeras
l
structur
function
protein
aid
deciph
molecular
mechan
filoviru
lifecycl
explanatorili
review
seri
three
review
martin
et
al
describ
aspect
filoviru
replic
assembl
briefli
gp
heterodimer
complex
surfac
protein
orchestr
viral
entri
host
cell
particip
viru
due
major
role
viral
entri
numer
approach
target
entri
process
explor
block
ebov
replic
earli
stage
name
antivir
molecul
broad
rang
small
molecul
review
rhein
specif
entri
inhibitor
target
fusion
event
character
entri
macropinocytosi
replic
transcript
cycl
involv
releas
viral
nucleocapsid
host
cell
cytoplasm
result
synthesi
new
viral
protein
genom
whole
process
assembl
bud
coordin
np
enhanc
np
bind
viral
rna
creat
rnp
complex
polymeras
l
viral
protein
np
play
import
role
multifunct
protein
suppress
immun
found
involv
transcriptionrepl
process
togeth
nucleocapsid
interact
protein
ie
essenti
regul
format
ebov
replic
complex
effici
transcriptionrepl
block
nucleocapsid
format
interact
inhibitor
lead
potenti
inhibit
ebov
exampl
peptid
first
identifi
np
ligand
specif
bind
np
block
np
oligomer
caus
releas
rna
studi
identifi
acid
potenti
disrupt
associ
complex
pyrrolidinon
recent
compound
specif
lead
specif
interact
function
nucleocapsid
matur
transcriptionrepl
addit
identifi
target
interact
inhibitor
name
macrocycl
peptid
inhibitor
karyopherin
specif
disrupt
matrix
protein
coordin
toward
viral
assembl
regul
viral
structuralfunct
featur
recent
advanc
crucial
regulatori
protein
essenti
viral
messeng
rna
mrna
synthesi
genom
replic
critic
therefor
constitut
key
target
design
drug
key
strategi
recogn
combat
ebov
includ
directli
target
viru
ii
modul
host
factor
immun
respons
iii
diseas
manag
critic
target
viral
lifecycl
among
popular
strategi
ebov
done
either
target
initi
bind
andor
entri
viru
host
cell
later
viral
replic
packag
ebov
antivir
compound
mainli
encompass
small
molecul
antisens
therapi
immunotherapeut
drug
current
treatment
evd
center
upon
modul
coagul
maintain
oxygen
level
ebola
therapeut
intervent
susten
recoveri
report
howev
signific
improv
might
observ
result
adequ
level
support
date
commerci
vaccin
specif
therapi
avail
ebov
howev
variou
studi
report
explain
comprehens
develop
repurpos
food
drug
administr
fda
approv
drug
tabl
provid
overview
compound
level
efficaci
report
either
vitro
assay
ebov
clinic
statu
observ
studi
develop
potent
small
molecul
direct
rna
polymeras
l
requir
viral
replic
promis
therapeut
three
potent
nucleotid
viral
polymeras
inhibitor
favipiravir
demonstr
vitro
anim
efficaci
mice
nhp
report
antivir
effect
due
intracellular
convers
correspond
nucleosid
triphosph
incorpor
viral
genom
inhibit
viral
polymeras
end
ebov
outbreak
clearli
indic
protect
rhesu
monkey
follow
lethal
ebov
improv
highli
potent
vitro
efficaci
mayinga
makona
strain
compar
moreov
recent
administ
first
time
newborn
test
inhibit
variou
virus
includ
arenavirus
bunyavirus
coronavirus
paramyxovirus
addit
anim
surviv
efficaci
account
rhesu
monkey
use
increas
dose
favipiravir
remain
potenti
candid
report
surviv
rate
mice
even
lowest
oral
dose
mgkg
daili
comparison
nhp
result
surviv
among
variou
fda
screen
multipl
compound
includ
amodiaquin
diphenylpyralin
ketotifen
diphenoxyl
report
inhibit
ebov
replic
other
includ
verapamil
dronedaron
sertralin
toremifen
chloroquin
teicoplanin
amiodaron
consid
ebov
entri
recent
tiloron
report
potent
inhibitor
dose
mgkg
intraperiton
prove
efficaci
protect
mice
lethal
ebov
inhibitor
shown
figur
studi
includ
identif
benzoquinolin
compound
compound
report
potent
compound
infecti
ebov
assay
ellag
acid
vindesin
prove
potenti
ebov
inhibit
direct
antivir
prevent
viral
entri
incorpor
larg
number
evd
treatment
recent
link
modul
immun
system
cytokin
chemokin
play
immunomodulatori
role
ebov
infect
promot
viral
clearanc
enhanc
immun
respons
howev
overwhelm
inflammatori
cytokin
releas
caus
undesir
effect
therefor
numer
research
group
current
identifi
studi
varieti
monoclon
antibodi
mab
lead
develop
sever
commerci
mab
cocktail
recent
ebov
gp
constitut
prime
target
therapeut
antibodi
zmab
cocktail
three
mous
mab
result
cocktail
three
chimer
mab
demonstr
protect
ebov
kikwit
strain
infect
rhesu
identifi
protect
combin
zmapp
introduc
combin
three
mab
demonstr
protect
rhesu
function
mechan
bind
zmapp
describ
neutral
activ
target
gp
base
glycan
studi
report
optim
zmapp
nhp
use
two
chimer
mab
design
protect
ebov
makona
strain
infect
rhesu
recent
mab
deliv
protect
ebov
infect
wherea
neutral
mab
reveal
also
coformul
cocktail
three
human
cocktail
ratio
current
evalu
prove
safe
well
toler
observ
immunogen
random
phase
clinic
trial
therapeut
includ
nucleic
inhibitor
phosphorodiamid
morpholino
oligom
pmo
rna
sirna
involv
promot
degrad
mrna
transcript
constitut
two
essenti
class
antisens
compound
target
vital
protein
involv
ebov
transcriptiontransl
process
viral
polymeras
l
develop
underli
modif
pmo
sirna
recent
pmo
combin
shown
signific
efficaci
safeti
direct
protect
alon
protect
without
develop
lipid
sirna
nanoparticl
product
target
viral
rna
polymeras
l
demonstr
surviv
advantag
phase
ii
without
develop
modif
addit
manag
evd
includ
treatment
clinic
manifest
like
hemorrhag
coagul
electrolyt
balanc
get
disturb
soon
viru
start
reproduc
spread
across
bodi
patient
requir
fluid
intak
intraven
oral
rich
electrolyt
treat
dehydr
restor
electrolyt
moreov
ebov
infect
result
disturb
blood
clot
purpos
anticoagul
like
recombin
nematod
anticoagul
protein
recombin
protein
c
rhapc
known
affect
coagul
pathway
investig
result
reduc
morbid
regardless
effect
treatment
evd
potenti
drug
candid
indic
promis
result
anim
model
safeti
efficaci
concern
aros
due
limit
durat
outbreak
reason
ebov
therapeut
advanc
develop
evalu
initi
two
phase
clinic
bafilomycin
chlorpromazin
cytochalasin
b
lectin
zmapp
report
inhibit
viral
mab
cocktail
develop
preclin
success
preclin
nhp
zmapp
recent
use
four
patient
evacu
success
treat
two
patient
repatri
unit
random
control
trial
prevail
ii
patient
demonstr
death
patient
treat
zmapp
compar
group
patient
receiv
standard
care
alon
death
patient
outbreak
two
promin
vaccin
rvsv
test
clinic
trial
prove
rvsv
current
phase
ii
test
unit
state
africa
viral
polymeras
sever
drug
report
success
cross
phase
clinic
trial
tabl
male
ebov
patient
current
test
reduct
viral
load
recent
antivir
activ
drug
discov
select
molecular
probe
identifi
ebov
infect
clomiphen
toremifen
select
estrogen
receptor
modul
serm
identifi
result
vitro
serm
block
ebola
entri
caus
reduct
accumul
endolysosom
calcium
concentr
cellular
approv
fda
treat
ebov
infect
although
outbreak
highlight
sever
therapeut
success
cross
phase
clinic
trial
indic
safeti
clinic
trial
conduct
outbreak
lack
proper
control
statist
power
due
sever
urgenc
amiodaron
reach
phase
ii
clinic
trial
sierra
leon
later
termin
due
lack
demonstr
efficaci
statist
fda
halt
releas
cytokin
trigger
action
sirna
caus
symptom
treat
likewis
brincidofovir
oral
bioactiv
molecul
fail
cross
phase
ii
clinic
trial
efficaci
safeti
toler
result
anoth
studi
jiki
trial
carri
test
efficaci
favipiravir
current
favipiravir
data
suggest
efficaci
low
moder
viral
trial
conduct
four
ebola
treatment
center
guinea
reli
use
histor
control
ambigu
result
jiki
critic
anoth
clinic
trial
nonrandom
carri
guinea
evalu
convalesc
plasma
fail
demonstr
improv
surviv
similarli
amodiaquin
show
good
invitro
efficaci
inhibit
ebov
show
toxic
effect
combinatori
two
consecut
outbreak
report
follow
year
may
govern
democrat
republ
congo
drc
report
evd
outbreak
zair
ebov
strain
countri
accord
last
updat
situat
report
equateur
drc
outbreak
juli
total
evd
case
laboratori
confirm
probabl
report
sinc
begin
outbreak
april
till
june
case
iboko
bikoro
wangata
health
zone
die
result
ratio
ninth
outbreak
drc
last
four
decad
sinc
last
outbreak
date
may
case
death
due
improv
efficaci
safeti
rvsv
evalu
individu
test
treatment
administ
drc
outbreak
current
investig
ring
vaccin
trial
phase
iii
declar
end
equateur
drc
outbreak
anoth
evd
outbreak
report
kivu
ituri
provinc
drc
august
octob
total
case
laboratori
confirm
probabl
report
includ
death
result
ratio
date
ongo
outbreak
drc
rais
seriou
concern
due
spread
surround
region
outbreak
investig
therapeut
includ
zmapp
remdesivir
monoclon
antibodi
use
first
time
treat
infect
individu
investig
togeth
rvsv
phase
ii
silico
method
drug
discoveri
hold
great
potenti
may
prove
benefici
stage
preclin
develop
drug
especi
area
like
target
valid
design
compound
hit
preclin
candid
identif
essenti
benefit
exponenti
increas
silico
tool
unpreced
accuraci
report
bayer
illustr
signific
integr
comput
drug
design
pharmaceut
compani
report
state
design
method
cadd
aid
approxim
half
new
chemic
entiti
current
test
phase
clinic
trial
figur
highlight
interconnect
stage
differ
phase
drug
discoveri
process
map
ebov
updat
protein
model
play
signific
role
drug
discoveri
process
goal
homolog
model
structur
predict
known
sequenc
accuraci
compar
experiment
resolv
restrict
link
techniqu
presenc
insert
loop
sequenc
accur
predict
absenc
crystal
gap
known
protein
sequenc
identifi
protein
structur
significantli
grow
given
enorm
amount
data
vast
array
dna
sequenc
techniqu
avail
experiment
structur
identif
techniqu
requir
comput
techniqu
activ
exploit
pharmaceut
industri
predict
protein
expand
scope
comput
method
improv
model
accuraci
effort
made
continu
approach
help
predict
tertiari
structur
protein
amino
acid
sequenc
combat
depend
avail
inform
method
character
either
de
novo
homolog
model
model
also
refer
homolog
model
compar
model
trust
method
model
similar
fold
properti
member
protein
famili
core
structur
unaffect
modif
sequenc
fundament
criteria
govern
homolog
model
gener
given
sequenc
structur
even
low
sequenc
similar
accur
model
obtain
use
homolog
templat
structur
initi
select
identifi
similar
experiment
determin
structur
sequenc
align
perform
model
energet
refin
optim
model
qualiti
refin
model
includ
optim
bond
length
angl
remov
clash
geometri
requir
addit
structur
modif
appli
relev
accur
model
obtain
howev
refin
model
often
meet
desir
level
number
potenti
silico
studi
document
last
year
includ
homolog
model
unresolv
ebov
virtual
screen
compound
potenti
bind
import
residu
line
bind
pocket
ebov
although
optim
interact
predict
molecular
key
interact
ligand
activ
site
receptor
accur
depict
henc
molecular
dock
follow
molecular
dynam
md
simul
obtain
complex
help
understand
interact
mode
rastelli
et
report
sulfonamid
deriv
bind
effect
within
activ
site
aldos
reductas
contrari
predict
experi
demonstr
lower
activ
bind
potenti
compound
therefor
negat
predict
made
later
silico
refin
compound
use
md
reveal
interrupt
key
interact
sulphonamid
ligand
receptor
due
addit
water
molecul
migrat
water
molecul
outsid
explain
reduc
activ
compound
test
anoth
studi
caval
et
md
simul
use
platform
discern
sever
differ
dock
complex
propidium
human
acetylcholinesteras
stabl
structur
identifi
correl
experiment
verifi
bind
mode
interestingli
md
simul
assist
discoveri
develop
antivir
first
time
combin
md
refin
postdock
complex
molecular
dock
help
reveal
uniqu
symmetr
bind
mode
daclatasvir
hepat
c
viru
hcv
protein
drug
current
phase
iii
clinic
trial
test
differ
hcv
moreov
md
simul
identif
trench
adjac
activ
site
integras
made
role
trench
ligand
bind
later
becam
evid
mutagenesi
studi
carri
find
help
design
potent
integras
inhibitor
enhanc
antivir
activ
structur
model
major
coreceptor
construct
use
md
furthermor
develop
antivir
drug
influenza
viru
ifv
also
benefit
md
simul
use
method
univers
caviti
adjac
bind
site
natur
substrat
report
neuraminidas
na
protein
human
pandem
avian
human
recent
md
simul
use
studi
molecular
behavior
zikv
presenc
absenc
rna
potenti
implic
recent
studi
report
notabl
exampl
drug
studi
prove
use
md
simul
understand
molecular
interact
mechan
drug
especi
optim
essenti
phase
close
examin
chemic
scaffold
concern
absorpt
distribut
metabol
excret
adm
challeng
drug
discoveri
process
silico
benefit
boost
repurpos
notion
design
drug
control
select
approach
aim
util
phenotyp
screen
hit
predict
potenti
target
mechan
action
ii
identifi
potenti
respons
advers
reaction
side
effect
iii
care
analysi
admet
absorpt
distribut
metabol
excret
toxic
paramet
propos
potenti
hit
anoth
use
silico
method
particularli
benefici
lead
optim
quantit
relationship
qspr
model
use
identif
key
structur
featur
respons
interact
target
protein
mani
adm
endpoint
measur
pharmaceut
industri
qspr
model
prospect
shown
abil
extract
knowledg
wide
varieti
chemic
scaffold
prove
util
predict
qspr
model
base
machin
learn
techniqu
desir
achiev
optim
potenc
adm
properti
reduc
risk
failur
trial
use
qsarqspr
model
necessari
accur
predict
activ
compound
drug
discoveri
project
howev
model
provid
adequ
inform
modif
made
test
compound
next
cycl
drug
design
address
issu
match
molecular
pair
analysi
techniqu
anoth
promis
approach
method
assess
mean
effect
differ
substitu
variou
adm
paramet
ii
iii
iv
cytochrom
design
new
scaffold
interact
desir
pharmacolog
target
benefit
base
find
molecular
substitut
close
link
molecular
properti
guid
design
scaffold
sever
studi
report
use
quantit
relationship
model
lead
comput
drug
discoveri
proven
acceler
challeng
process
design
optim
new
drug
candid
hierarch
virtual
screen
method
delin
valid
find
potenti
hit
even
earli
phase
drug
discoveri
increas
effici
ebola
optim
interplay
sever
stage
silico
drug
design
depict
figur
rapid
develop
faster
architectur
comprehens
algorithm
comput
impact
comput
drug
design
antivir
drug
discoveri
lead
optim
profound
impact
futur
year
hit
identif
also
elucid
biolog
target
provid
inform
use
drug
discoveri
research
perspect
perilla
et
describ
physic
properti
capsid
protein
use
md
simul
andoh
et
perform
md
calcul
studi
entir
polioviru
found
rapid
equilibrium
exchang
water
molecul
across
capsid
final
conclud
capsid
function
semiperm
membran
next
studi
le
et
less
restrict
singl
target
studi
drug
interact
tamiflu
relenza
multipl
evolutionari
correl
protein
specif
swine
influenza
spanish
avian
flu
na
investig
use
md
techniqu
possibl
drug
resist
mechan
combin
electrostat
analysi
research
group
creat
molecular
model
swine
influenza
na
base
avian
na
three
na
simul
compar
bound
state
oseltamivir
tamiflu
zanamivir
relenza
compar
simul
identifi
conserv
uniqu
interact
across
three
protein
mediat
hydrogen
bond
elucid
key
molecular
interact
use
predict
mutat
could
lead
drug
resist
advanc
nudg
elast
band
catalyt
md
techniqu
identifi
reaction
conform
transit
advanc
hybrid
qmmm
md
simul
proven
extrem
benefici
gain
profound
insight
reaction
mechan
involv
investig
biosystem
specif
ass
amino
acid
interact
energi
decoupl
potenti
identifi
key
interact
target
mani
drug
candid
known
bind
less
popul
structur
within
target
conform
space
view
dock
describ
method
ligand
dock
multipl
conform
form
biomolecular
target
instead
one
base
hypothesi
influenc
induc
fit
enzym
analysi
could
prove
help
elucid
collect
motion
protein
domain
underli
conform
chang
upon
bind
research
slow
motion
extract
md
trajectori
use
princip
compon
analysi
md
simul
techniqu
might
incorpor
elucid
interact
amino
acid
target
ligand
interest
describ
use
energi
decoupl
steer
md
simul
appli
predefin
degre
freedom
use
identifi
catalyt
import
domain
movement
target
relat
ligand
bind
refin
qualiti
postdock
complex
gener
assess
plot
squar
deviat
squar
fluctuat
obtain
trajectori
comparison
purpos
complex
system
energi
calcul
use
molecular
mechan
surfac
areagener
born
surfac
area
incorpor
workflow
like
numer
recent
studi
perform
aid
md
simul
search
direct
investig
drug
resist
furthermor
comput
power
increas
exponenti
past
year
sequenti
develop
power
supercomput
unit
comput
assumpt
continu
moor
law
reason
given
latest
advanc
comput
power
increas
process
power
expect
howev
quantum
comput
becom
realiti
maximum
level
process
power
expect
due
limit
comput
resourc
special
supercomput
design
especi
md
simul
develop
show
abil
reach
millisecond
timescal
repres
interest
biolog
effort
made
quantum
comput
offer
excit
date
actual
quantum
comput
still
initi
stage
develop
quantum
comput
oper
execut
experiment
small
number
quantum
bit
timewis
develop
might
becom
possibl
simul
larg
biolog
system
determin
comput
fold
protein
start
amino
acid
drug
discoveri
process
applic
promis
especi
target
identif
interact
analysi
success
rate
drug
discoveri
pipelin
involv
target
identif
screen
optim
preclin
candid
select
within
rang
failur
discoveri
project
account
sever
reason
notabl
unclear
underli
mechan
target
protein
ii
lack
lead
iii
poor
potenc
iv
lack
efficaci
v
inappropri
properti
vi
unexpect
high
level
howev
success
rate
clinic
develop
drug
vari
distinctli
experiment
drug
phase
clinic
trial
approxim
chanc
reach
inadequ
efficaci
drug
account
recent
phase
iii
clinic
trial
failur
half
trial
phase
ii
trial
approxim
phase
drug
fail
clinic
trial
even
though
experiment
drug
enter
human
clinic
trial
base
extens
preclin
data
indic
efficaci
vivo
moreov
experi
ebola
strain
requir
safeti
level
narrow
possibl
slow
progress
drug
research
complex
human
biolog
amplifi
limit
drug
discoveri
pose
signific
challeng
magnitud
recent
ebov
outbreak
coupl
drug
discoveri
develop
challeng
necessit
need
explor
altern
strategi
despit
current
countermeasur
experiment
drug
vaccin
develop
progress
earliest
stage
product
develop
repurpos
drug
provid
altern
way
acceler
process
drug
design
discoveri
investig
compound
new
direct
open
avenu
devis
strategi
challeng
diseas
particular
evd
drug
gain
fda
approv
rigor
screen
set
criteria
includ
pharmacokinet
pharmacodynam
dosag
toxic
safeti
efficaci
repurpos
drug
bypass
phase
clinic
trial
acceler
drug
discoveri
process
addit
elimin
logist
consider
like
manufactur
distribut
howev
repurpos
drug
unfavor
data
gain
clinic
trial
may
serv
purpos
approv
drug
might
cut
develop
timelin
furthermor
studi
mechan
action
repurpos
drug
may
difficult
therefor
experi
specif
design
identifi
mechan
action
repurpos
compound
may
provid
insight
ebov
lifecycl
help
devis
new
trial
evd
pandem
addit
drug
resist
also
major
clinic
problem
treatment
individu
small
number
mutat
drastic
chang
biolog
properti
rna
hiv
influenza
statist
power
preclin
studi
crucial
effici
clinic
studi
prevent
unnecessari
test
larg
number
larg
proport
drug
proceed
clinic
trial
never
show
anim
efficaci
lead
larg
number
useless
moreov
statist
power
clinic
studi
pose
addit
challeng
enrol
suffici
number
particip
clinic
trial
demonstr
statist
signific
anim
model
need
reliabl
enough
reflect
patient
situat
furthermor
overal
aspect
experiment
procedur
efficaci
estim
higher
addit
pharmacokinet
properti
particularli
plasma
repres
drug
efficaci
use
anim
model
import
interspeci
translat
becom
evid
light
recent
clinic
trial
although
mani
treatment
option
evd
propos
exist
drug
yet
genet
immunolog
profil
vari
one
popul
anoth
pose
challeng
evalu
drug
safeti
profil
differ
popul
identifi
viabl
hit
silico
hit
identif
screen
almost
achiev
target
howev
optim
remain
cumbersom
reason
argument
comput
method
accur
predict
bind
constant
chemic
divers
compound
larg
dataset
still
need
optim
second
admet
properti
difficult
predict
larg
dataset
imposs
simplifi
singl
molecular
event
incontrovert
admet
properti
caus
failur
drug
candid
increas
attent
paid
pharmacokinet
properti
lead
optim
result
poor
pharmacokinet
properti
major
issu
today
account
clinic
failur
mostli
phase
joint
effort
regulatori
institut
analysi
control
experiment
protocol
perform
yield
safe
unpreced
predict
result
human
clinic
trial
largest
devast
ebola
outbreak
effort
toward
evd
treatment
gain
vital
import
outbreak
highlight
urgent
need
develop
efficaci
treatment
use
curtail
futur
outbreak
result
clinic
research
numer
countermeasur
develop
includ
vaccin
vaccin
nucleosid
nucleotid
analogu
favipiravir
plasma
transfus
immunotherapeut
zmapp
nucleic
drug
repurpos
drug
scientif
commun
overcom
multipl
challeng
ensur
licens
efficaci
drug
futur
outbreak
regard
requir
widen
prospect
develop
therapeut
agent
activ
filovirus
like
marburg
viru
sudan
viru
viral
pathogen
howev
drug
discoveri
develop
pipelin
lead
small
number
compound
enter
clinic
trial
thu
make
challeng
also
process
next
outbreak
drug
develop
effort
reli
efficaci
character
anim
model
evd
ebov
outbreak
also
reconfirm
signific
immunolog
basi
vaccin
protect
scientif
commun
help
assist
progress
vaccin
candid
develop
also
vaccin
efficaci
assess
potenti
outbreak
genet
divers
strain
come
episod
within
entir
process
drug
discoveri
author
great
potenti
attribut
silico
method
drug
discoveri
may
prove
benefici
stage
preclin
develop
drug
candid
silico
drug
discoveri
method
alreadi
chang
percept
drug
design
develop
method
comput
chemistri
particularli
md
simul
qspr
significantli
impact
trajectori
drug
discoveri
process
pharmaceut
industri
increas
understand
human
biolog
clinic
trial
expect
gain
success
md
simul
case
make
use
contribut
understand
underli
molecular
process
biolog
function
applic
qspr
model
improvis
abil
design
better
molecul
achiev
goal
presenc
enorm
amount
data
comput
approach
sought
method
answer
biolog
problem
advanc
understand
mechan
mode
action
ebov
futur
silico
work
essenti
role
develop
drug
candid
devast
evd
